— Know what they know.
Not Investment Advice

207940.KS

Samsung Biologics Co.,Ltd.
1W: -2.5% 1M: -7.7% 3M: -15.6% YTD: -7.3% 1Y: -4.6% 3Y: +29.8% 5Y: +28.5%
₩1,585,000.00 ($1,054)
-3000.00 (-0.19%)
 
KSC · Healthcare · Biotechnology · ₩73.37T
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap₩73.37T ($48.8B)
52W Range1501000-1987000
Volume39,127
Avg Volume58,067
Beta0.20
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOJohn Chongbo Rim
Employees4,770
SectorHealthcare
IndustryBiotechnology
IPO Date2016-11-11
300, Songdo Bio-daero
Incheon 21987
KR
82 3 2455 3114
About Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms